Session Information
Date: Wednesday, September 25, 2019
Session Title: Non-Motor Symptoms
Session Time: 1:15pm-2:45pm
Location: Agora 3 West, Level 3
Objective: To evaluat of gut microbiota in patients with Parkinson’s disease using a gas chromatography–mass spectrometry
Background: An increasing number of studies have reported the crosstalk between gut microbiota and the host brain in Parkinson`s disease. However, the results of studies on the evaluation of the composition of microbiota contradict each other. That is due to the use of various methods. Using a gas chromatography–mass spectrometry (GC-MS) is uniquely suitable for obtaining the metabolic signals in bidirectional communication between gut microbiota and brain.
Method: We compared the gut microbiota composition of 16 patients with stage 3 of Parkinson’s disease (9 female) and 94 age-matched controls using GC-MS with detection of small molecule metabolites (SMMs) in serum. We used an Agilent 7890a gas chromatograph.
Results: We observed significant increases in the abundance of SMMs by 43% in patients with PD compared to those of the controls. The abundance of conditionally pathogenic gut microbes was increased in patients with PD: Staphylococcus intermedius – in 61%, Eubacterium lentum (group A) – by 5,8 times, Clostridium hystolyticum – by 2,8 times, Peptostreptococ. Anaerobius – by 3,6 times, Ruminicoccus – by 3,8 times, Nocardia and Nocardia asteroides – by 2 times, Clostridium propionicum and Enterobacteriaceae family (E. coli and other), Micro-fungi, cytosterol by 1,7 times, Micro-fungi, campesterol and Herpes by 2,8 times. Identified decreases in the abundance of SMMs of Streptococcus, Cl. difficile, Propionibacterium jensenii, Propionibacterium acnes by 2 times. At the same time the SMMs number of useful gut microbes was decreased: Eubacterium/Cl.coccoides – by 6,3 times, Bifidobacterium – by 2,5 times, Propionibacterium/Cl. subterm. – by 1,5 times, Lactobacillus – on 24%.
Conclusion: Using a gas chromatography–mass spectrometry is probably the most objective method for assessing the gut microbiota, which allows for a minimally invasive but widespread assessment of gut dysbiosis in Parkinson’s disease with a view to its further correction.
To cite this abstract in AMA style:
I. Krasakov, I. Litvinenko. Evaluation of gut microbiota in patients with Parkinson’s disease using a gas chromatography–mass spectrometry in Russia [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/evaluation-of-gut-microbiota-in-patients-with-parkinsons-disease-using-a-gas-chromatography-mass-spectrometry-in-russia/. Accessed November 21, 2024.« Back to 2019 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/evaluation-of-gut-microbiota-in-patients-with-parkinsons-disease-using-a-gas-chromatography-mass-spectrometry-in-russia/